[New opportunities of using gialuronidase in chronic prostatitis]

Area of Science:

• Urology
• Pharmacology

Background:

• Hyaluronidase, like in Longidaza, improves microcirculation and reduces inflammation in chronic prostatitis.
• This mechanism suggests Longidaza's potential for diagnosing latent bacterial prostatitis.

Purpose of the Study:

• To evaluate the diagnostic and therapeutic efficacy of Longidaza rectal suppositories in chronic prostatitis patients.
• Assessing Longidaza's role in routine clinical practice for diagnosing and treating prostatitis.

Main Methods:

• A prospective study involving 39 men with chronic prostatitis (categories II and IIIa).
• Expressed prostate secretion (EPS) analyzed microbiologically at baseline, after initial Longidaza use, and after 7 weeks of therapy.
• Longidaza administered every 48-72 hours, with antibiotic therapy initiated upon pathogen isolation.

Main Results:

• Longidaza use increased pathogen detection from 69.2% to 82% and provoked inflammation in 58.3% of initially abacterial cases.
• Post-treatment, pathogen detection decreased to 17.9%, with significant reductions in pain (NIH-CPSI scale from 17.3 to 3.9) and dysuria.
• Patient quality of life improved significantly.

Conclusions:

• Bacterial prostatitis is frequently undiagnosed.
• Longidaza rectal suppositories are effective for diagnosing latent bacterial prostatitis by enhancing pathogen and inflammation detection.
• Longidaza demonstrates significant therapeutic benefits in managing chronic prostatitis symptoms.